An arthritis drug owned by Pfizer may reduce the risk of developing Alzheimer's according to a report by the Washington Post.
However the pharmaceutical giant has decided not to develop the drug, Enbrel, for Alzheimer's.
Critics say this is because the patent on the drug will soon expire and Alzheimer’s trials are long and expensive because the disease progresses slowly.